ライフサイエンスコーパス: nonvalvular atrial fibrillation

1 on alternative to warfarin for patients with nonvalvular atrial fibrillation.

2 ation to reduce stroke risk in patients with nonvalvular atrial fibrillation.

3 he Amulet occluder (Abbott) in patients with nonvalvular atrial fibrillation.

4 r preventing DRT after LAAC in patients with nonvalvular atrial fibrillation.

5 rials comparing VKAs and NOACs (n=71 681) in nonvalvular atrial fibrillation.

6 dent than in the management of patients with nonvalvular atrial fibrillation.

7 farin in stroke prevention for patients with nonvalvular atrial fibrillation.

8 and risk of major bleeding in patients with nonvalvular atrial fibrillation.

9 farin for stroke prevention in patients with nonvalvular atrial fibrillation.

10 ly INR-stable warfarin-treated patients with nonvalvular atrial fibrillation.

11 eventing ischemic stroke among patients with nonvalvular atrial fibrillation.

12 uperior to warfarin for stroke prevention in nonvalvular atrial fibrillation.

13 oral anticoagulants or VKA in patients with nonvalvular atrial fibrillation.

14 pared with warfarin in elderly patients with nonvalvular atrial fibrillation.

15 icant thromboembolic events in patients with nonvalvular atrial fibrillation.

16 g in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation.

17 with warfarin for patients at risk who have nonvalvular atrial fibrillation.

18 duced intracranial bleeding in patients with nonvalvular atrial fibrillation.

19 or stroke prevention in 18 113 patients with nonvalvular atrial fibrillation.

20 7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation.

21 d antithrombotic agents in patients who have nonvalvular atrial fibrillation.

22 strokes in a cohort of 13,559 patients with nonvalvular atrial fibrillation.

23 n patients with mechanical cardiac valves or nonvalvular atrial fibrillation.

24 e initial management strategy for persistent nonvalvular atrial fibrillation.

25 romboembolic risk reduction in patients with nonvalvular atrial fibrillation.

26 ulation to prevent embolic events related to nonvalvular atrial fibrillation.

27 e to anticoagulation in select patients with nonvalvular atrial fibrillation.

28 Of 13,559 adults with nonvalvular atrial fibrillation, 11,526 were studied, 43

29 spirin and P2Y12 inhibitor) in patients with nonvalvular atrial fibrillation (AF) after percutaneous

30 on) trial demonstrated that in patients with nonvalvular atrial fibrillation (AF) and CHADS2 (congest

31 use of oral anticoagulation in patients with nonvalvular atrial fibrillation (AF) is a major issue th

32 cy of left atrial appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible

33 appendage occlusion (LAAO) in patients with nonvalvular atrial fibrillation (AF) remains uncertain.

34 arin for stroke prophylaxis in patients with nonvalvular atrial fibrillation (AF).

35 al, Minneapolis, Minnesota) in patients with nonvalvular atrial fibrillation and absolute contraindic

36 Patients (n=707) with nonvalvular atrial fibrillation and at least 1 risk fact

37 Cs compared with VKAs to treat patients with nonvalvular atrial fibrillation and concomitant aspirin

38 t the analyses to those newly diagnosed with nonvalvular atrial fibrillation and naive-to-treatment,

39 was a man age 69 years with newly diagnosed nonvalvular atrial fibrillation and no contraindications

40 Of 11082 patients with nonvalvular atrial fibrillation and no known contraindic

41 ulation included 5386 patients with incident nonvalvular atrial fibrillation and type 2 diabetes mell

42 r long-term anticoagulation in patients with nonvalvular atrial fibrillation, and document the lowest

43 Among patients with nonvalvular atrial fibrillation, anticoagulation that re

44 Patients with nonvalvular atrial fibrillation are at increased risk of

45 bigatran versus warfarin in the treatment of nonvalvular atrial fibrillation are lacking.

46 In patients with nonvalvular atrial fibrillation at high risk of cardioem

47 Patients with nonvalvular atrial fibrillation at increased risk of str

48 to dabigatran and warfarin in patients with nonvalvular atrial fibrillation at risk for stroke witho

49 e-dummy study of rivaroxaban and warfarin in nonvalvular atrial fibrillation, baseline characteristic

50 as the first-choice therapy in patients with nonvalvular atrial fibrillation because these drugs have

51 harged from the hospital with a diagnosis of nonvalvular atrial fibrillation between 1997 and 2008.

52 ated dabigatran or warfarin for treatment of nonvalvular atrial fibrillation between October 2010 and

53 ool in reducing stroke risk in patients with nonvalvular atrial fibrillation but is underused.

54 n preventing stroke and systemic embolism in nonvalvular atrial fibrillation, but has not been evalua

55 ally reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambul

56 be cost-effective for typical patients with nonvalvular atrial fibrillation, but may be cost-effecti

57 with Watchman provides stroke prevention in nonvalvular atrial fibrillation comparable to warfarin,

58 y and effectiveness of stroke prevention for nonvalvular atrial fibrillation compared with the Watchm

59 mes) among older individuals with cancer and nonvalvular atrial fibrillation comparing DOACs and warf

60 Among patients taking NOACs for nonvalvular atrial fibrillation, concurrent use of amiod

61 ith VKA in anticoagulant-naive patients with nonvalvular atrial fibrillation during the early phase o

62 ischemic strokes and emboli in patients with nonvalvular atrial fibrillation from 4.5% to 1.4% per ye

63 lants (DOAC) over warfarin to treat isolated nonvalvular atrial fibrillation, guidelines are silent r

64 Patients with nonvalvular atrial fibrillation have a 4- to 5-fold incr

65 Strategies in patients with nonvalvular atrial fibrillation have included anticoagul

66 oke risk prediction schemes in patients with nonvalvular atrial fibrillation, highlight the strengths

67 lable to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effec

68 Patients diagnosed with nonvalvular atrial fibrillation in a 4-hospital institut

69 dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice sett

70 s with type 2 diabetes mellitus and incident nonvalvular atrial fibrillation in the period of May 1,

71 HMAN FLX LAA closure device in patients with nonvalvular atrial fibrillation in whom oral anticoagula

72 Nonvalvular atrial fibrillation is a major cause of thro

73 Nonvalvular atrial fibrillation is common in elderly pat

74 rect oral anticoagulants among patients with nonvalvular atrial fibrillation is not known.

75 Nonvalvular atrial fibrillation is the most common arrhy

76 ith dabigatran and warfarin in patients with nonvalvular atrial fibrillation is unknown.

77 onist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major bleeding events,

78 Among 91330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [S

79 Physicians managing patients with nonvalvular atrial fibrillation must consider the risks,

80 Stented subjects with nonvalvular atrial fibrillation (n=2124) were randomized

81 Many patients with nonvalvular atrial fibrillation (NVAF) are at a high ris

82 lants (DOACs) are approved for patients with nonvalvular atrial fibrillation (NVAF) at high risk of b

83 reduces the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) but increases the

84 unction is associated with increased risk of nonvalvular atrial fibrillation (NVAF) in older adults w

85 verse events regarding stroke prevention for nonvalvular atrial fibrillation (NVAF) in the direct ora

86 The objective of this study is to describe nonvalvular atrial fibrillation (NVAF) incidence in Engl

87 f acute kidney injury (AKI) in patients with nonvalvular atrial fibrillation (NVAF) remains unknown.

88 stemic embolism, and cardiovascular death in nonvalvular atrial fibrillation (NVAF) requires continue

89 nsomnia, non-small cell lung cancer (NSCLC), nonvalvular atrial fibrillation (NVAF) stroke prevention

90 illation) trial that evaluated patients with nonvalvular atrial fibrillation (NVAF), left atrial appe

91 oembolic risk, particularly in patients with nonvalvular atrial fibrillation (NVAF).

92 efficacy and safety outcomes in Asians with nonvalvular atrial fibrillation (NVAF).

93 litus (DM) increases the risk of embolism in nonvalvular atrial fibrillation (NVAF). The association

94 trospective cohort study of 1876 adults with nonvalvular atrial fibrillation or flutter seen in prima

95 We included 6022 nonvalvular atrial fibrillation patients from 912 center

96 Among nonvalvular atrial fibrillation patients treated with da

97 compare persistence rates in newly diagnosed nonvalvular atrial fibrillation patients treated with wa

98 hed data of patients >/=18 years of age with nonvalvular atrial fibrillation, randomized to either VK

99 d effectiveness outcomes among patients with nonvalvular atrial fibrillation receiving oral anticoagu

100 LAAC) for stroke prevention in patients with nonvalvular atrial fibrillation remain limited.

101 We identified 1 141 097 patients with nonvalvular atrial fibrillation; the mean (SD) age was 7

102 troke and systemic embolism in patients with nonvalvular atrial fibrillation; transcatheter aortic va

103 ibrillation, guidelines are silent regarding nonvalvular atrial fibrillation treatment among individu

104 A total of 52 patients with nonvalvular atrial fibrillation underwent LAAC with the

105 New users of anticoagulants with nonvalvular atrial fibrillation were followed until a st

106 tran prescriptions between 2010 and 2012 for nonvalvular atrial fibrillation were sampled (4863 total

107 e an alternative treatment for patients with nonvalvular atrial fibrillation who are less than optima

108 We randomly assigned 2124 participants with nonvalvular atrial fibrillation who had undergone PCI wi

109 tionwide cohort study included patients with nonvalvular atrial fibrillation who initiated dabigatran

110 igible participants were adult patients with nonvalvular atrial fibrillation who initiated oral antic

111 older) undergoing dialysis with a history of nonvalvular atrial fibrillation who met the CHADS-65 cri

112 cluded individuals diagnosed with cancer and nonvalvular atrial fibrillation who newly initiated DOAC

113 e database and including 91330 patients with nonvalvular atrial fibrillation who received at least 1

114 ility of SDD versus non-SDD in patients with nonvalvular atrial fibrillation who underwent LAAC.

115 l, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased ri

116 ied 39,400 patients discharged with incident nonvalvular atrial fibrillation with 0 or 1 CHA2DS2-VASc

117 United States is indicated in patients with nonvalvular atrial fibrillation with acceptable anatomy